Navigation Links
Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
Date:10/27/2010

had received at least one prior therapy and five patients were treated in the first-line setting.(1)  This Part 2 expansion cohort study of patients with ALK-positive advanced NSCLC, independent of the number of previous chemotherapies, followed the completion of the dose-escalation study which enrolled 37 advanced cancer patients with various tumors, including NSCLC, colorectal, pancreatic and inflammatory myofibroblastic tumor (IMT) tumors.(8)

These data were previously presented at the 2010 American Society of Clinical Oncology Annual Meeting.(7)

About Crizotinib (PF-02341066)

Crizotinib (PF-02341066) is a first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK,(3) and is representative of Pfizer's personalized medicine approach to cancer treatment.  By inhibiting ALK, crizotinib (PF-02341066) blocks signaling in a number of cell pathways that may be critical for the growth and survival of tumor cells.(4)  Crizotinib (PF-02341066) is also an inhibitor of c-MET (mesenchymal endothelial transition factor).(3)

About Non-Small Cell Lung Cancer

Lung cancer is one of the most common cancers worldwide.(9)  NSCLC accounts for about 85 percent of lung cancer cases and remains difficult to treat, particularly in the metastatic setting. Approximately 75 percent of NSCLC patients are diagnosed late with metastatic, or advanced, disease, where the five-year survival rate is only 6 percent.(10,11)  In addition, the current standard of care for advanced NSCLC demonstrates a response rate of only about 15 percent.(12)  Approximately 3-5 percent of NSCLC tumors are ALK-positive.(4)

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline, one of the most robust in the industry, is studied
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Since last month,s FBI shutdown of online drug ... leading online black market for illegal drugs - Evolution ... of drugs and other illegal items.  New numbers from ... in lowering the numbers of drugs and illegal items ... August. But some new sites that have emerged as ...
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
Breaking Medicine Technology:Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3ZEISS confirma su posición en un entorno difícil 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
(Date:12/19/2014)... (HealthDay News) -- Potentially illness-causing E. coli bacteria were ... markets, according to a new study. Researchers checked ... 13 farmers markets in Los Angeles and Orange counties ... almost 150 samples tested, 24 percent were positive for ... to the researchers. Both types of bacteria can ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Dense bunches of ... and cancers, a new study finds. The researchers ... of the colon. The presence of these biofilms may ... a new way to predict a person,s risk for the ... on pond stones, these biofilms may coat the mucus layer ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Older adults who ... and walking ability than people who still have at least ... findings suggest that total tooth loss could provide an early ... older people, the British researchers said. However, the findings ... decline. The study included more than 3,100 participants 60 ...
(Date:12/19/2014)... Diet Doc strives to continue to ... weight loss by combining scientific fast weight ... the company understand that remaining committed to a diet ... carbohydrates and sugars from the diet can cause patients ... weight loss goals. , For this reason, Diet ...
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Estes Park, Colo. The top executive ... has recently placed more than 900 healthcare executives into ... a 25-bed, not-for-profit critical access hospital and level IV ...
Breaking Medicine News(10 mins):Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Could Bacteria Play a Role in Colon Cancer? 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3
... based on successful,management of nearly 45,000 cases ... NEWPORT NEWS, Va., June 17 ... organization providing direct,case management services and healthcare ... and chronic diseases each year who are,unable ...
... Ore., June 17 Your 83-year old widowed mother,can no ... facility. But she is in,Florida, and you live in California. ... for a suitable assisted living or nursing,home in a strange ... care facility in the western United States and Florida. Available ...
... to help miilions of children in developing world, ... A new compound that may lead to an inexpensive, ... at the University of Texas Health Science Center at ... for developing countries, where diarrhea is a major cause ...
... , The use of the growth hormone in oral ... the integration between the bone base and the dental implant. ... weeks the wait time to place the crown which replaces ... been the resulto f the research of the doctoral thesis ...
... wait to see a doctor could get a lot longer ... care physicians doesn,t increase soon, according to a new University ... community medicine in the MU School of Medicine, and his ... of up to 44,000 family physicians and general internists in ...
... June 17 Among US primary care physicians,Novartis ... by,Pfizer, Merck, GlaxoSmithKline and Sanofi-Aventis, according to new,research ... spot in Europe,demonstrating a consistent ability to build ... rep relationship scores, it has,greater variability in Europe, ...
Cached Medicine News:Health News:Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance 2Health News:New Resource Available for Families Seeking Quality Care for Aging Parents 2Health News:Inexpensive Compound Could Treat Severe Diarrhea 2Health News:Scientists from Granada drastically reduce the wait time for new teeth implant 2Health News:US could face shortage of 44,000 primary care physicians by 2025 2Health News:US could face shortage of 44,000 primary care physicians by 2025 3Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 2Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 3Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 4
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
... is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqueous ... the anterior or posterior segment, through the ... are easily and accurately identified utilizing endoscopy. ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
Medicine Products: